01—Abstract
Summary
Summary of the 10-K filed March 12, 2007. Cited figures are marked; the original filing is the authoritative source.
Alnylam Pharmaceuticals (ALNY) reported its FY2006 10-K, filed March 2007, describing a clinical-stage biopharmaceutical company built around RNA interference (RNAi) therapeutics.
Its lead program, ALN-RSV01 for respiratory syncytial virus, has been in Phase I trials since December 2005, with an inhaled formulation and a human challenge study added in late 2006. Other development programs cover pandemic flu (with Novartis) and hypercholesterolemia (ALN-PCS01, targeting PCSK9), alongside discovery programs in CNS disease, cystic fibrosis, PML and Ebola. The company remains unprofitable and has no approved products.
Revenue is almost entirely collaboration-based, with Novartis contributing about 81% of 2006 revenue. Financially, 2006 net revenues rose to $26.9 milliona from $5.7 million, while the net loss narrowed slightly to $34.6 million from $42.9 million, helped by higher interest income. Operating expenses grew to $66.4 million, led by R&D of $49.8 million.
The accumulated deficit reached $140.5 millionb. Liquidity improved substantially: cash, cash equivalents and marketable securities totaled $217.3 million at year-end, up from $80.0 million, after roughly $163 million of net proceeds from January and December 2006 follow-on offerings. Management states that existing resources plus expected collaboration cash should fund operations for at least several years.
Key risks for investors include the unproven nature of RNAi as a drug class, dependence on Novartis (which holds about 14%c of shares and has an option to integrate Alnylam's IP and compete), the Kreutzer-Limmer patent being challenged in European oppositions, and the reliance on government contracts such as the NIAID Ebola award. Future dilution from equity raises is a continuing concern.
02—Key points
Key Highlights
- Revenue grew about 371% to $26.9 million in 2006, driven mainly by a full year of Novartis collaboration activity ($21.8 million from Novartis, versus $0.7 million in 2005).
- Net loss narrowed to $34.6 million ($1.09 per share) from $42.9 million ($1.96 per share) in 2005, though the company remains unprofitable with an accumulated deficit of $140.5 million.
- Cash, cash equivalents and marketable securities rose to $217.3 million at December 31, 2006, from $80.0 million, following about $163.3 million of net proceeds from January and December 2006 public offerings.
- Lead program ALN-RSV01 (RSV) is in Phase I trials, with an inhaled formulation study started in October 2006 and a human experimental infection study started in November 2006.
- Partnerships include Novartis (pandemic flu and a broad alliance), Merck, Medtronic, Biogen Idec, Isis, and a NIAID contract worth up to $23.0 million for Ebola antiviral work.
- Novartis owned about 14% of common stock at year-end 2006 and holds an option to integrate Alnylam IP that could make it a competitor, which is a key concentration risk.
- Operating expenses increased 35% to $66.4 million, with R&D at $49.8 million (up 41%) reflecting RSV clinical trial costs and expanded headcount, and non-cash stock compensation rising to $8.3 million after adopting SFAS 123R.
03—Questions
Frequently Asked Questions
Does Alnylam have any approved products or near-term commercial revenue?
No. The 10-K states the company has not developed or sold any products and does not expect product revenue in the foreseeable future. Revenue comes from collaborations with Novartis and Merck, government contracts, and InterfeRx and research-reagent licenses. Management expects most revenue over the next several years to come from these sources.
How dependent is Alnylam on Novartis?
Heavily. Novartis accounted for about 81% of 2006 revenue and held roughly 14% of common stock at year-end 2006. The company expects a substantial part of its operating funding to come from the Novartis collaboration. Risks include the possibility of early termination, the non-exclusive option that would let Novartis integrate Alnylam's IP and compete, and a right of first offer on targets Novartis did not select.
Is the company funded enough to continue operations?
Management believes existing resources, together with expected collaboration cash, will fund planned operations for at least the next several years, with $217.3 million in cash and marketable securities at year-end 2006. The filing warns that funding may be needed earlier than expected to start clinical trials for new candidates, and that future equity raises could dilute existing stockholders.
What are the main patent and legal risks?
Alnylam holds or licenses key siRNA patents, including the Tuschl II patents (US 7,056,704 and 7,078,196) and the Kreutzer-Limmer European patents. The EP 1144623 patent was upheld with amended claims in June 2006 but has been appealed by opponents including Sirna (now owned by Merck), and other oppositions are pending in Europe and Australia. The company says it is not currently a party to any material legal proceedings.
What are the biggest scientific and regulatory uncertainties for RNAi drugs?
The filing notes that no RNAi therapeutic has received regulatory approval, and that the FDA may regulate these products as biologics rather than new drugs. Scientific concerns include off-target effects, interferon response activation, and delivering siRNAs stably into target cells. Competitors such as Acuity (bevasiranib, in Phase II/III plans) and Isis (antisense drugs, more advanced in development) are also ahead in some areas.
04—Continue